Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases.

Patel S, Webster JD, Varfolomeev E, Kwon YC, Cheng JH, Zhang J, Dugger DL, Wickliffe KE, Maltzman A, Sujatha-Bhaskar S, Bir Kohli P, Ramaswamy S, Deshmukh G, Liederer BM, Fong R, Hamilton G, Lupardus P, Caplazi P, Lee WP, van Lookeren Campagne M, Johnson A, McKenzie BS, Junttila MR, Newton K, Vucic D.

Cell Death Differ. 2019 May 17. doi: 10.1038/s41418-019-0347-0. [Epub ahead of print]

PMID:
31101885
2.

The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation.

Senger K, Pham VC, Varfolomeev E, Hackney JA, Corzo CA, Collier J, Lau VWC, Huang Z, Hamidzhadeh K, Caplazi P, Peng I, Setiadi AF, Francis R, Paler-Martinez A, Kwon YC, Ramirez-Carrozzi V, Sun Y, Grigg PW, Roose-Girma M, Jeet S, Barck KH, Pham A, Ota N, Ha C, Stinson J, Guillory J, Tam L, Modrusan Z, Emson C, McKenzie BS, Townsend MJ, Carano RAD, Warming S, Vucic D, DeVoss J, Lee WP, Lill JR, Zarrin AA.

Sci Signal. 2017 Apr 18;10(475). pii: eaah4273. doi: 10.1126/scisignal.aah4273.

PMID:
28420753
3.

Intracellular regulation of TNF activity in health and disease.

Varfolomeev E, Vucic D.

Cytokine. 2018 Jan;101:26-32. doi: 10.1016/j.cyto.2016.08.035. Epub 2016 Sep 9. Review.

PMID:
27623350
4.

Coordinated ubiquitination and phosphorylation of RIP1 regulates necroptotic cell death.

de Almagro MC, Goncharov T, Izrael-Tomasevic A, Duttler S, Kist M, Varfolomeev E, Wu X, Lee WP, Murray J, Webster JD, Yu K, Kirkpatrick DS, Newton K, Vucic D.

Cell Death Differ. 2017 Jan;24(1):26-37. doi: 10.1038/cdd.2016.78. Epub 2016 Aug 12.

5.

Immunoaffinity enrichment coupled to quantitative mass spectrometry reveals ubiquitin-mediated signaling events.

Yu K, Phu L, Varfolomeev E, Bustos D, Vucic D, Kirkpatrick DS.

J Mol Biol. 2015 Jun 5;427(11):2121-34. doi: 10.1016/j.jmb.2015.03.018. Epub 2015 Apr 8.

PMID:
25861760
6.

Roles of c-IAP proteins in TNF receptor family activation of NF-κB signaling.

Varfolomeev E, Goncharov T, Vucic D.

Methods Mol Biol. 2015;1280:269-82. doi: 10.1007/978-1-4939-2422-6_15.

PMID:
25736754
7.

Ubiquitination profiling identifies sensitivity factors for IAP antagonist treatment.

Varfolomeev E, Izrael-Tomasevic A, Yu K, Bustos D, Goncharov T, Belmont LD, Masselot A, Bakalarski CE, Kirkpatrick DS, Vucic D.

Biochem J. 2015 Feb 15;466(1):45-54. doi: 10.1042/BJ20141195.

PMID:
25423073
8.

OTUB1 modulates c-IAP1 stability to regulate signalling pathways.

Goncharov T, Niessen K, de Almagro MC, Izrael-Tomasevic A, Fedorova AV, Varfolomeev E, Arnott D, Deshayes K, Kirkpatrick DS, Vucic D.

EMBO J. 2013 Apr 17;32(8):1103-14. doi: 10.1038/emboj.2013.62. Epub 2013 Mar 22.

9.

Characterization of ML-IAP protein stability and physiological role in vivo.

Varfolomeev E, Moradi E, Dynek JN, Zha J, Fedorova AV, Deshayes K, Fairbrother WJ, Newton K, Le Couter J, Vucic D.

Biochem J. 2012 Nov 1;447(3):427-36. doi: 10.1042/BJ20121103.

PMID:
22853455
10.

Cellular inhibitors of apoptosis are global regulators of NF-κB and MAPK activation by members of the TNF family of receptors.

Varfolomeev E, Goncharov T, Maecker H, Zobel K, Kömüves LG, Deshayes K, Vucic D.

Sci Signal. 2012 Mar 20;5(216):ra22. doi: 10.1126/scisignal.2001878.

11.

Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).

Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, Cohen F, Deshayes K, Doerner K, Eckhardt SG, Elliott LO, Feng B, Franklin MC, Reisner SF, Gazzard L, Halladay J, Hymowitz SG, La H, LoRusso P, Maurer B, Murray L, Plise E, Quan C, Stephan JP, Young SG, Tom J, Tsui V, Um J, Varfolomeev E, Vucic D, Wagner AJ, Wallweber HJ, Wang L, Ware J, Wen Z, Wong H, Wong JM, Wong M, Wong S, Yu R, Zobel K, Fairbrother WJ.

J Med Chem. 2012 May 10;55(9):4101-13. doi: 10.1021/jm300060k. Epub 2012 Mar 28.

12.

Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination.

Dueber EC, Schoeffler AJ, Lingel A, Elliott JM, Fedorova AV, Giannetti AM, Zobel K, Maurer B, Varfolomeev E, Wu P, Wallweber HJ, Hymowitz SG, Deshayes K, Vucic D, Fairbrother WJ.

Science. 2011 Oct 21;334(6054):376-80. doi: 10.1126/science.1207862.

13.

Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets.

Varfolomeev E, Vucic D.

Future Oncol. 2011 May;7(5):633-48. doi: 10.2217/fon.11.40. Review.

PMID:
21568679
14.

Targeting inhibitor of apoptosis proteins for therapeutic intervention.

Ndubaku C, Cohen F, Varfolomeev E, Vucic D.

Future Med Chem. 2009 Nov;1(8):1509-25. doi: 10.4155/fmc.09.116. Review.

PMID:
21426063
15.

X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists.

Varfolomeev E, Alicke B, Elliott JM, Zobel K, West K, Wong H, Scheer JM, Ashkenazi A, Gould SE, Fairbrother WJ, Vucic D.

J Biol Chem. 2009 Dec 11;284(50):34553-60. doi: 10.1074/jbc.M109.040139. Epub 2009 Oct 23.

16.

Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists.

Ndubaku C, Varfolomeev E, Wang L, Zobel K, Lau K, Elliott LO, Maurer B, Fedorova AV, Dynek JN, Koehler M, Hymowitz SG, Tsui V, Deshayes K, Fairbrother WJ, Flygare JA, Vucic D.

ACS Chem Biol. 2009 Jul 17;4(7):557-66. doi: 10.1021/cb900083m.

PMID:
19492850
17.

Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1).

Blankenship JW, Varfolomeev E, Goncharov T, Fedorova AV, Kirkpatrick DS, Izrael-Tomasevic A, Phu L, Arnott D, Aghajan M, Zobel K, Bazan JF, Fairbrother WJ, Deshayes K, Vucic D.

Biochem J. 2009 Jan 1;417(1):149-60. doi: 10.1042/BJ20081885.

PMID:
18939944
18.

c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation.

Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, Fairbrother WJ, Vucic D.

J Biol Chem. 2008 Sep 5;283(36):24295-9. doi: 10.1074/jbc.C800128200. Epub 2008 Jul 11.

19.

(Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways.

Varfolomeev E, Vucic D.

Cell Cycle. 2008 Jun 1;7(11):1511-21. Epub 2008 Mar 16. Review.

PMID:
18469528
20.

IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis.

Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D.

Cell. 2007 Nov 16;131(4):669-81.

21.

Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.

Zobel K, Wang L, Varfolomeev E, Franklin MC, Elliott LO, Wallweber HJ, Okawa DC, Flygare JA, Vucic D, Fairbrother WJ, Deshayes K.

ACS Chem Biol. 2006 Sep 19;1(8):525-33. Erratum in: ACS Chem Biol. 2006 Oct 20;1(9):601.

PMID:
17168540
22.

The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 AND TRAF2.

Varfolomeev E, Wayson SM, Dixit VM, Fairbrother WJ, Vucic D.

J Biol Chem. 2006 Sep 29;281(39):29022-9. Epub 2006 Aug 4.

23.

Delineation of the cell-extrinsic apoptosis pathway in the zebrafish.

Eimon PM, Kratz E, Varfolomeev E, Hymowitz SG, Stern H, Zha J, Ashkenazi A.

Cell Death Differ. 2006 Oct;13(10):1619-30. Epub 2006 Aug 4.

24.

Death-receptor activation halts clathrin-dependent endocytosis.

Austin CD, Lawrence DA, Peden AA, Varfolomeev EE, Totpal K, De Mazière AM, Klumperman J, Arnott D, Pham V, Scheller RH, Ashkenazi A.

Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10283-10288. doi: 10.1073/pnas.0604044103. Epub 2006 Jun 26. Erratum in: Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13560.

25.

MORT1/FADD is involved in liver regeneration.

Schuchmann M, Ruckert F, Garcia-Lazaro JF, Karg A, Burg J, Knorr N, Siebler J, Varfolomeev EE, Wallach D, Schreiber W, Lohse AW, Galle PR.

World J Gastroenterol. 2005 Dec 14;11(46):7248-53.

26.

TWEAK attenuates the transition from innate to adaptive immunity.

Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, Hurst S, Danilenko D, Li J, Filvaroff E, Yang B, Daniel D, Ashkenazi A.

Cell. 2005 Dec 2;123(5):931-44.

27.

Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.

Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A.

J Biol Chem. 2005 Dec 9;280(49):40599-608. Epub 2005 Oct 15.

28.

Caspase-8 serves both apoptotic and nonapoptotic roles.

Kang TB, Ben-Moshe T, Varfolomeev EE, Pewzner-Jung Y, Yogev N, Jurewicz A, Waisman A, Brenner O, Haffner R, Gustafsson E, Ramakrishnan P, Lapidot T, Wallach D.

J Immunol. 2004 Sep 1;173(5):2976-84.

29.

Tumor necrosis factor: an apoptosis JuNKie?

Varfolomeev EE, Ashkenazi A.

Cell. 2004 Feb 20;116(4):491-7. Review.

30.

APRIL-deficient mice have normal immune system development.

Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, Lawrence D, Olsson C, Tom L, Erickson S, French D, Schow P, Grewal IS, Ashkenazi A.

Mol Cell Biol. 2004 Feb;24(3):997-1006.

31.

Dominant negative MORT1/FADD rescues mice from CD95 and TNF-induced liver failure.

Schuchmann M, Varfolomeev EE, Hermann F, Rueckert F, Strand D, Koehler H, Strand S, Lohse AW, Wallach D, Galle PR.

Hepatology. 2003 Jan;37(1):129-35.

PMID:
12500197
32.

How are the regulators regulated? The search for mechanisms that impose specificity on induction of cell death and NF-kappaB activation by members of the TNF/NGF receptor family.

Wallach D, Arumugam TU, Boldin MP, Cantarella G, Ganesh KA, Goltsev Y, Goncharov TM, Kovalenko AV, Rajput A, Varfolomeev EE, Zhang SQ.

Arthritis Res. 2002;4 Suppl 3:S189-96. Epub 2002 May 9. Review.

33.

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A.

Nat Med. 2002 Mar;8(3):274-81.

PMID:
11875499
34.

Tumor necrosis factor receptor and Fas signaling mechanisms.

Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP.

Annu Rev Immunol. 1999;17:331-67. Review.

PMID:
10358762
35.

Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally.

Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL, Rebrikov D, Brodianski VM, Kemper OC, Kollet O, Lapidot T, Soffer D, Sobe T, Avraham KB, Goncharov T, Holtmann H, Lonai P, Wallach D.

Immunity. 1998 Aug;9(2):267-76.

36.

Death-inducing functions of ligands of the tumor necrosis factor family: a Sanhedrin verdict.

Wallach D, Kovalenko AV, Varfolomeev EE, Boldin MP.

Curr Opin Immunol. 1998 Jun;10(3):279-88. Review.

PMID:
9638364
37.

CASH, a novel caspase homologue with death effector domains.

Goltsev YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskii VM, Wallach D.

J Biol Chem. 1997 Aug 8;272(32):19641-4.

38.

Cell death induction by receptors of the TNF family: towards a molecular understanding.

Wallach D, Boldin M, Varfolomeev E, Beyaert R, Vandenabeele P, Fiers W.

FEBS Lett. 1997 Jun 23;410(1):96-106. Review. No abstract available.

39.

[A polymorphic markers for the p75 tumor necrosis factor receptor gene: use for analyzing disease linkage].

Turetskaia RL, Varfolomeev EE, Lopukhina AA, Udalova IA, Kuprash DV, Krasil'nikov AN, Chaplin DD, Nedospasov SA.

Dokl Akad Nauk. 1996 Dec;351(4):558-60. Russian. No abstract available.

PMID:
9116596
40.

Exploring cell death mechanisms by analyzing signaling cascades of the TNF/NGF receptor family.

Wallach D, Boldin M, Goncharov T, Goltsev Y, Mett I, Malinin N, Adar R, Kovalenko A, Varfolomeev E.

Behring Inst Mitt. 1996 Oct;(97):144-55. Review.

PMID:
8950472
42.

The death domain: a module shared by proteins with diverse cellular functions.

Feinstein E, Kimchi A, Wallach D, Boldin M, Varfolomeev E.

Trends Biochem Sci. 1995 Sep;20(9):342-4. No abstract available.

PMID:
7482697
43.

A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain.

Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D.

J Biol Chem. 1995 Apr 7;270(14):7795-8.

44.

Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects.

Boldin MP, Mett IL, Varfolomeev EE, Chumakov I, Shemer-Avni Y, Camonis JH, Wallach D.

J Biol Chem. 1995 Jan 6;270(1):387-91.

45.

Structural requirements for inducible shedding of the p55 tumor necrosis factor receptor.

Brakebusch C, Varfolomeev EE, Batkin M, Wallach D.

J Biol Chem. 1994 Dec 23;269(51):32488-96.

Supplemental Content

Loading ...
Support Center